Alkaptonuria
A rare genetic metabolic disorder
Alkaptonuria | |
---|---|
![]() | |
Synonyms | Black urine disease, black bone disease, alcaptonuria |
Pronounce | |
Field | Medical genetics, metabolic medicine |
Symptoms | Dark urine, bluish-black discoloration of connective tissues and skin (ochronosis), joint pain, arthritis, heart valve disease, kidney and prostate stones |
Complications | Severe arthritis, heart disease, renal stones, pigmentation of skin and eyes |
Onset | Symptoms often appear in adulthood (30s–40s), but dark urine may be seen in infancy |
Duration | Lifelong |
Types | Autosomal recessive metabolic disorder |
Causes | Deficiency of the enzyme homogentisate 1,2-dioxygenase (HGD gene mutation) |
Risks | Family history, consanguinity, autosomal recessive inheritance |
Diagnosis | Urine organic acid analysis, genetic testing, elevated homogentisic acid in urine |
Differential diagnosis | Maple syrup urine disease, phenylketonuria, ochronosis from exogenous sources |
Prevention | None known |
Treatment | Symptomatic management, physical therapy, joint replacement surgery in advanced cases |
Medication | Nitisinone (off-label use), pain relievers |
Prognosis | Progressive; joint and cardiac complications may reduce quality of life |
Frequency | Rare (approximately 1 in 250,000 to 1,000,000 live births) |
Deaths | Related to complications (e.g., cardiac or renal) |
Alkaptonuria is a rare genetic disorder characterized by the accumulation of homogentisic acid in the body. This condition is caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase, which is necessary for the proper breakdown of tyrosine and phenylalanine, two important amino acids.
Pathophysiology[edit | edit source]
In individuals with alkaptonuria, the lack of functional homogentisate 1,2-dioxygenase leads to the accumulation of homogentisic acid in the body. This acid is excreted in the urine, which can turn dark upon exposure to air, a hallmark of the condition. Over time, homogentisic acid also deposits in connective tissues, leading to a condition known as ochronosis. This results in the darkening of tissues, particularly affecting the cartilage and skin.
Clinical Features[edit | edit source]
The clinical manifestations of alkaptonuria typically appear in adulthood, although the darkening of urine can be observed in infancy. The major symptoms include:
- Ochronosis: The deposition of pigment in connective tissues, leading to darkened ear cartilage and sclera of the eyes.
- Arthropathy: Progressive joint disease due to the accumulation of pigment in the cartilage, leading to osteoarthritis, particularly in the spine, knees, and hips.
- Cardiovascular complications: Deposition of pigment in the heart valves can lead to valvular heart disease.
- Renal stones: Increased risk of kidney stones due to the accumulation of homogentisic acid.
Diagnosis[edit | edit source]
The diagnosis of alkaptonuria is primarily based on clinical features and the detection of elevated levels of homogentisic acid in the urine. Genetic testing can confirm mutations in the HGD gene, which encodes the enzyme homogentisate 1,2-dioxygenase.

Management[edit | edit source]
There is currently no cure for alkaptonuria, and treatment is primarily supportive. Management strategies include:
- Dietary modification: Reducing intake of phenylalanine and tyrosine may help decrease homogentisic acid levels.
- Pain management: Use of analgesics and anti-inflammatory drugs to manage joint pain.
- Physical therapy: To maintain joint function and mobility.
- Surgical intervention: Joint replacement surgery may be necessary for severe arthropathy.
Prognosis[edit | edit source]
The prognosis for individuals with alkaptonuria varies. While the condition is chronic and progressive, many individuals can manage symptoms effectively with appropriate care. However, the risk of complications such as severe arthritis and cardiovascular issues can impact quality of life.
Related pages[edit | edit source]
External links[edit | edit source]
Classification | |
---|---|
External resources |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD